Abstract
Tacrolimus (FK506) is a new macrolide immunosuppressant isolated from Streptomyces tsukubaenesis that acts by a variety of different mechanisms, including inhibition of calcineurin. Although the mechanism of action of tacrolimus is similar to that of ciclosporin A, tacrolimus is 10 to 100 times more potent. Tacrolimus also has an effect on glucocorticoid receptor-mediated gene expression. The therapeutic efficacy of tacrolimus in primary immunosuppression has been evaluated in numerous clinical trials in patients receiving hepatic, renal, heart, lung, pancreas, intestinal, or bone marrow transplantation. Because tacrolimus displays a variety of different mechanisms of action and shows a synergism with corticosteroids, it is presumed that tacrolimus provides a new and useful therapeutic approach for autoimmune diseases, including myasthenia gravis.
Keywords: Anti-cholinesterase inhibitors, corticosteroids, immunosuppressant, FK-506 binding proteins (FKBP)-12, CYP enzyme
Current Drug Therapy
Title: Tacrolimus Treatment in Myasthenia Gravis
Volume: 2 Issue: 1
Author(s): Naoki Kawaguchi
Affiliation:
Keywords: Anti-cholinesterase inhibitors, corticosteroids, immunosuppressant, FK-506 binding proteins (FKBP)-12, CYP enzyme
Abstract: Tacrolimus (FK506) is a new macrolide immunosuppressant isolated from Streptomyces tsukubaenesis that acts by a variety of different mechanisms, including inhibition of calcineurin. Although the mechanism of action of tacrolimus is similar to that of ciclosporin A, tacrolimus is 10 to 100 times more potent. Tacrolimus also has an effect on glucocorticoid receptor-mediated gene expression. The therapeutic efficacy of tacrolimus in primary immunosuppression has been evaluated in numerous clinical trials in patients receiving hepatic, renal, heart, lung, pancreas, intestinal, or bone marrow transplantation. Because tacrolimus displays a variety of different mechanisms of action and shows a synergism with corticosteroids, it is presumed that tacrolimus provides a new and useful therapeutic approach for autoimmune diseases, including myasthenia gravis.
Export Options
About this article
Cite this article as:
Kawaguchi Naoki, Tacrolimus Treatment in Myasthenia Gravis, Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422437
DOI https://dx.doi.org/10.2174/157488507779422437 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oral Tolerance in the Treatment of Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Recent Developments in the Discovery of Selective Glucocorticoid Receptor Modulators (SGRMs)
Current Topics in Medicinal Chemistry HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets Natural Killer T Cells and Autoimmune Disease
Current Molecular Medicine Further Vitamin D Analogs
Current Vascular Pharmacology Identification of Expressed miRNAs in Human Rheumatoid Arthritis Using Computational Approach – Discovery of a New miR-7167 from Human
MicroRNA Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Approaches to the Therapy of Rheumatoid Arthritis based on an Understanding of Disease Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Polyreactive Antibodies in Anti-HIV-1 Responses
Current Molecular Medicine Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) T Cell-Activated Signaling Pathways and Locally Produced Cytokines as Potential Targets in Celiac Disease
Current Drug Targets Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine